A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection

Judith E. Feinberg, Shelley Hurwitz, David Cooper, Fred R. Sattler, Rob Roy MacGregor, William Powderly, Gary N. Holland, Paul D. Griffiths, Richard B Pollard, Michael Youle, M. John Gill, Fiona J. Holland, Maureen E. Power, Susan Owens, Dion Coakley, John Fry, Mark A. Jacobson

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalJournal of Infectious Diseases
Volume177
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

valacyclovir
Virus Diseases
Cytomegalovirus
Acyclovir
HIV
Survival
Valine
Risk Reduction Behavior
CD4 Lymphocyte Count
Oral Administration

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Feinberg, J. E., Hurwitz, S., Cooper, D., Sattler, F. R., MacGregor, R. R., Powderly, W., ... Jacobson, M. A. (1998). A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases, 177(1), 48-56.

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. / Feinberg, Judith E.; Hurwitz, Shelley; Cooper, David; Sattler, Fred R.; MacGregor, Rob Roy; Powderly, William; Holland, Gary N.; Griffiths, Paul D.; Pollard, Richard B; Youle, Michael; John Gill, M.; Holland, Fiona J.; Power, Maureen E.; Owens, Susan; Coakley, Dion; Fry, John; Jacobson, Mark A.

In: Journal of Infectious Diseases, Vol. 177, No. 1, 1998, p. 48-56.

Research output: Contribution to journalArticle

Feinberg, JE, Hurwitz, S, Cooper, D, Sattler, FR, MacGregor, RR, Powderly, W, Holland, GN, Griffiths, PD, Pollard, RB, Youle, M, John Gill, M, Holland, FJ, Power, ME, Owens, S, Coakley, D, Fry, J & Jacobson, MA 1998, 'A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection', Journal of Infectious Diseases, vol. 177, no. 1, pp. 48-56.
Feinberg, Judith E. ; Hurwitz, Shelley ; Cooper, David ; Sattler, Fred R. ; MacGregor, Rob Roy ; Powderly, William ; Holland, Gary N. ; Griffiths, Paul D. ; Pollard, Richard B ; Youle, Michael ; John Gill, M. ; Holland, Fiona J. ; Power, Maureen E. ; Owens, Susan ; Coakley, Dion ; Fry, John ; Jacobson, Mark A. / A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. In: Journal of Infectious Diseases. 1998 ; Vol. 177, No. 1. pp. 48-56.
@article{ede212fab3bb474d9f700d59500b54fe,
title = "A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection",
abstract = "Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7{\%} among valaciclovir recipients and 17.5{\%} in the pooled acyclovir arms, a 33{\%} reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.",
author = "Feinberg, {Judith E.} and Shelley Hurwitz and David Cooper and Sattler, {Fred R.} and MacGregor, {Rob Roy} and William Powderly and Holland, {Gary N.} and Griffiths, {Paul D.} and Pollard, {Richard B} and Michael Youle and {John Gill}, M. and Holland, {Fiona J.} and Power, {Maureen E.} and Susan Owens and Dion Coakley and John Fry and Jacobson, {Mark A.}",
year = "1998",
language = "English (US)",
volume = "177",
pages = "48--56",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection

AU - Feinberg, Judith E.

AU - Hurwitz, Shelley

AU - Cooper, David

AU - Sattler, Fred R.

AU - MacGregor, Rob Roy

AU - Powderly, William

AU - Holland, Gary N.

AU - Griffiths, Paul D.

AU - Pollard, Richard B

AU - Youle, Michael

AU - John Gill, M.

AU - Holland, Fiona J.

AU - Power, Maureen E.

AU - Owens, Susan

AU - Coakley, Dion

AU - Fry, John

AU - Jacobson, Mark A.

PY - 1998

Y1 - 1998

N2 - Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.

AB - Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.

UR - http://www.scopus.com/inward/record.url?scp=6844258215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844258215&partnerID=8YFLogxK

M3 - Article

C2 - 9419169

AN - SCOPUS:6844258215

VL - 177

SP - 48

EP - 56

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -